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RESEARCH ARTICLE
SGTA regulates the cytosolic quality control of hydrophobic
substrates
Lydia Wunderley, Pawel Leznicki*, Aishwarya Payapilly and Stephen High`
ABSTRACT
Hydrophobic amino acids are normally shielded from the cytosol and
their exposure is often used as an indicator of protein misfolding to
enable the chaperone-mediated recognition and quality control of
aberrant polypeptides. Mislocalised membrane proteins (MLPs)
represent a particular challenge to cellular quality control, and, in
this study, membrane protein fragments have been exploited to study
a specialised pathway that underlies the efficient detection and
proteasomal degradation of MLPs. Our data show that the BAG6
complex and SGTA compete for cytosolic MLPs by recognition of
their exposed hydrophobicity, and the data suggest that SGTA acts to
maintain these substrates in a non-ubiquitylated state. Hence, SGTA
might counter the actions of BAG6 to delay the ubiquitylation of
specific precursors and thereby increase their opportunity for
successful post-translational delivery to the endoplasmic reticulum.
However, when SGTA is overexpressed, the normally efficient
removal of aberrant MLPs is delayed, increasing their steady-state
level and promoting aggregation. Our data suggest that SGTA
regulates the cellular fate of a range of hydrophobic polypeptides
should they become exposed to the cytosol.
KEY WORDS: Aggresomes, BAG6, Mislocalised membrane
proteins, Polyubiquitylation, Protein degradation, Small glutamine-
rich tetratricopeptide repeat-containing protein alpha
INTRODUCTION
Hydrophobic amino acids are typically buried within the tertiary
structure of a protein, and their inappropriate exposure can be
exploited by cellular quality control components as an indicator
of misfolding (Buchberger et al., 2010). The contiguous stretches
of hydrophobic amino acids that characterise integral membrane
proteins provide a particularly extreme and aggregation-prone
indicator of misfolding when such polypeptides mislocalise to the
cytosol (Ast and Schuldiner, 2011; Leznicki et al., 2013; Rodrigo-
Brenni and Hegde, 2012). For membrane proteins entering the
eukaryotic secretory pathway, their signal recognition particle
(SRP)-dependent delivery to the endoplasmic reticulum (ER) and
subsequent co-translational integration by the Sec61 translocon
effectively reduces the opportunity for any cytosolic exposure of
their transmembrane domains. Hence, the first transmembrane
domain to emerge from the ribosomes acts as an ER-targeting
signal that is bound to and shielded by the SRP54 subunit (Cross
et al., 2009), whereas any subsequent hydrophobic regions will be
protected from the cytosol by a combination of the ribosome and
ER translocon (Hou et al., 2012).
In practice, the efficiency of SRP-dependent targeting is
influenced by various factors, including the hydrophobicity and
location of the ER-targeting signal (Goder et al., 2000), and the
process is also subject to regulation (Swanton and High, 2006).
Furthermore, a number of membrane and secretory proteins are
delivered to the ER by post-translational SRP-independent
pathways that might also result in the mislocalisation of some
precursors to the cytosol (Ast et al., 2013; Johnson et al., 2013;
Rodrigo-Brenni and Hegde, 2012). Whatever their precise origin,
it is clear that higher eukaryotes have a distinct quality control
pathway that deals with mislocalised membrane and secretory
proteins (MLPs) (Hessa et al., 2011; Kawahara et al., 2013;
Leznicki and High, 2012; Rodrigo-Brenni and Hegde, 2012).
Notably, key components that mediate MLP quality control also
contribute to the ER-associated degradation (ERAD) of misfolded
membrane proteins and the biogenesis of selected precursors
destined for the ER (Johnson et al., 2013; Leznicki et al., 2010;
Mariappan et al., 2010; Rodrigo-Brenni and Hegde, 2012).
The BAG6 complex and the small glutamine-rich
tetratricopeptide repeat-containing protein a (SGTA) play a
central role in dictating the fate of MLPs (Hessa et al., 2011;
Leznicki and High, 2012) and promote the insertion of tail-
anchored proteins into the ER membrane (Kawahara et al., 2013;
Leznicki et al., 2010; Leznicki et al., 2013; Leznicki et al., 2011;
Mariappan et al., 2010). In the latter case, BAG6 and SGTA act
upstream of an ATP-dependent targeting factor, TRC40 (also
known as ASNA1) (Chartron et al., 2012; Leznicki et al., 2010;
Mariappan et al., 2010), which delivers precursors to the ER for
post-translational membrane insertion and translocation (Favaloro
et al., 2008; Johnson et al., 2012; Stefanovic and Hegde, 2007).
During the cytosolic quality control of aberrant precursors,
BAG6 and SGTA appear to act in tandem to control the
polyubiquitylation status, and hence proteasomal degradation, of
MLPs. Previous studies have suggested that BAG6 acts to
promote the polyubiquitylation of hydrophobic substrates,
including MLPs (Hessa et al., 2011; Minami et al., 2010),
whereas SGTA antagonises this process by enabling substrate
deubiquitylation (Leznicki and High, 2012). This functional
overlap between SGTA and the BAG6 complex is mirrored by
a specific physical interaction between an SGTA dimer and
ubiquitin-like domains present on subunits of the BAG6 complex
(Chartron et al., 2012; Leznicki et al., 2013; Simon et al., 2013;
Xu et al., 2012). Furthermore, both components are also
implicated in the ERAD of aberrant membrane proteins
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synthesised at the ER (Claessen and Ploegh, 2011; Wang et al.,
2011; Xu et al., 2012; Xu et al., 2013). Hence, SGTA and the
BAG6 complex appear to deal with a range of substrates
that feature cytosolically exposed regions of hydrophobicity,
including transmembrane regions that are not membrane
embedded (Kawahara et al., 2013; Leznicki et al., 2013).
In this study, we have focused on the role of SGTA during the
specific recognition and degradation of aberrant membrane
protein precursors that expose a hydrophobic degron to the
cytosol. To this end, we have used short N-terminal fragments of
polytopic membrane proteins to create model MLPs, and we
studied their fate following perturbations of SGTA and BAG6 in
mammalian cells. One of these MLPs, a fragment of TASK1 (also
known as KCNK3) with an opsin N-glycosylation tag (OPG–
TASK85), is almost exclusively mislocalised to the cytosol and
interacts with both BAG6 and SGTA through its hydrophobic
transmembrane domain. Consistent with their suggested opposing
actions, the steady-state level of OPG–TASK85 is specifically
increased upon BAG6 knockdown but reduced upon SGTA
knockdown. The overexpression of exogenous SGTA selectively
stabilises MLP and ERAD substrates by delaying their normal
proteasomal degradation. This non-physiological stabilisation of
MLPs requires SGTA to maintain an intact BAG6-binding
site, and our data suggest that SGTA can promote MLP
deubiquitylation. In a physiological context, such substrate
deubiquitylation most likely provides a potential rescue
pathway that is employed by specific precursors such as tail-
anchored membrane proteins. We conclude that the combined
actions of SGTA and the BAG6 complex normally act to
ensure the efficient removal of MLPs, thereby preventing
their accumulation and potential aggregation and minimising
potentially harmful perturbations of normal cellular proteostasis
(Buchberger et al., 2010; Chakrabarti and Hegde, 2009; Hartl
et al., 2011; Park et al., 2013), whilst at the same time promoting
the correct maturation of selected hydrophobic precursor proteins
destined for the ER.
RESULTS
Previous studies have suggested that SGTA regulates the fate of
aberrant membrane proteins that are localised in the cytosol as a
consequence of both inefficient delivery to (Leznicki and High,
2012), and retrotranslocation from (Xu et al., 2012), the ER.
Naturally occurring nonsense mutations sometimes generate very
short hydrophobic fragments derived from complex membrane
proteins including opsin (Jacobson et al., 1994), and we
speculated that such polypeptides might be especially prone to
cytosolic mislocalisation (see also Heymann and Subramaniam,
1997), thereby providing potential model substrates for studying
the role of SGTA during the cytosolic quality control of MLPs.
Exogenous SGTA increases the steady-state level of
cytosolic MLPs
During a study of TASK-1 biogenesis, we found that a short N-
terminal fragment, incorporating only the first of its four
transmembrane spans, was efficiently inserted into ER-derived
microsomes when synthesised using a cell-free system (Watson
et al., 2013). By contrast, when the same TASK-1-derived
fragment (hereafter referred to as OPG–TASK85, Fig. 1A) was
expressed in HeLa cells we found no evidence for its membrane
insertion. Hence, OPG–TASK85 is not detectably N-glycosylated
at either N- or C-terminal reporters (Fig. 1B, cf. lanes 2 and 3).
By contrast, increasing the chain length of the truncated TASK-1
derivative by only 15 residues, to create OPG–TASK100, resulted
in clearly detectable levels of N-glycosylation (Fig. 1A, OPG–
TASK100; Fig. 1B, cf. lanes 2–5). Subcellular fractionation
(Fig. 1C, cf. lanes 5, 6, 8 and 9) and immunofluorescence
microscopy (Fig. 1D) confirmed that most, if not all, of
the shorter OPG–TASK85 chains were cytosolic, whereas a
substantial proportion of the slightly longer OPG–TASK100
chains were associated with the ER membrane. The
mislocalisation of OPG–TASK85 to the cytosol is most likely a
consequence of a decreased window of opportunity for SRP
to bind to the first transmembrane domain (TM1), the only
ER-targeting signal present in the truncated TASK-1-derived
fragment, before translation termination occurs in vivo (Goder
et al., 2000), thereby precluding its efficient co-translational
delivery to the ER (Cross et al., 2009). In this scenario, extending
the C-terminus of the TASK-1-derived fragment by as little as
fifteen residues would increase the likelihood of successful SRP-
dependent co-translational targeting to the ER.
The recognition of MLPs by key components implicated in
their cytosolic quality control, namely the BAG6 complex
and SGTA, appears to rely on exposed hydrophobic residues,
including non-membrane-inserted transmembrane domains
(Hessa et al., 2011; Leznicki and High, 2012). We therefore
used OPG–TASK85 as a candidate MLP (Fig. 1) in order to test
the role of cytosolically exposed hydrophobicity in directing
proteins towards a specific pathway for degradation (cf. Leznicki
and High, 2012). To this end, we generated OPG–TASK85 R4, an
alternative version of OPG–TASK85 where the transmembrane
region is strongly perturbed by the introduction of two pairs of
arginine residues (supplementary material Fig. S1A,B; cf. Hessa
et al., 2011). Overexpression has been used to study the role of
several components implicated in protein quality control and
degradation (cf. Christianson et al., 2012; Fleig et al., 2012;
Guerriero and Brodsky, 2012; Liu et al., 2014), and we found that
the coexpression of exogenous SGTA increased the steady-state
level of OPG–TASK85 substantially (Fig. 2A, cf. lanes 2 and 3),
consistent with our previous study (Leznicki and High, 2012).
Furthermore, the steady-state level of OPG–TASK85 correlated
with the amount of exogenous SGTA that was expressed,
suggesting that it is the total amount of cellular SGTA that
influences the level of OPG–TASK85 (Fig. 2B). By contrast,
SGTA expression had little if any effect on OPG–TASK85 R4
(Fig. 2A, cf. lanes 6 and 7), although steady-state levels of both
forms of OPG–TASK85 were increased upon treatment with the
proteasome inhibitor bortezomib (Fig. 2A, cf. lanes 2, 4, 6 and 8).
We conclude that although both TASK-1-derived fragments are
substrates for proteasomal degradation, only the removal of the
OPG–TASK85 substrate with an intact transmembrane region that
acts as a ‘hydrophobic degron’ (cf. Minami et al., 2010) is
affected by the perturbation of cellular SGTA levels.
In vitro analysis suggested that a short N-terminal segment of
opsin might also be a substrate for SGTA-mediated quality
control (Leznicki and High, 2012), and when this OP91 fragment
(Fig. 2C) was transiently expressed in HeLa cells alone,
the resulting products were only faintly visible by western
blotting (Fig. 2D, lane 1). Treatment with bortezomib resulted in
a substantial increase in OP91 levels, whereas inhibitors of
lysosomal degradation had no effect, suggesting that OP91 is
subject to proteasomal degradation (supplementary material
Fig. S1C). Most strikingly, we also observed a large increase in
the level of OP91 upon SGTA coexpression (approximately
sevenfold enhancement; Fig. 2D; supplementary material
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 4728–4739 doi:10.1242/jcs.155648
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Fig. S1D). It should be noted that both bortezomib treatment and
SGTA coexpression selectively enhanced the levels of a discrete
non-N-glycosylated OP91 species (OP91 0-CH0), consistent
with the proposal that opsin-derived polypeptides located in
the cytosol are selectively stabilised in both cases (Fig. 2D;
supplementary material Fig. S1C,D). However, unlike bortezomib,
the effects of SGTA coexpression were substrate specific, and the
proteasomal degradation of an N-end rule substrate, Ub-R–GFP
was unaffected (supplementary material Fig. S1E). Taken
together, these data indicate that a substantial proportion of
OP91 acts as an MLP that fails to reach the ER and defaults to the
cytosol, where it acts as a substrate for BAG6- and SGTA-
mediated quality control (cf. Hessa et al., 2011; Leznicki and
High, 2012).
In order to further test the role of cellular SGTA in the quality
control of MLPs, we reduced the level of the endogenous protein
using an siRNA approach and studied the effect on steady-state
OPG–TASK85. The loss of cellular SGTA resulted in a reduction
in the amount of OPG–TASK85 (Fig. 2E, cf. lanes 1 and 2;
supplementary material Fig. S1F), the opposite to the effect of
SGTA overexpression (Fig. 2B). Likewise, a knockdown of
SGTA also resulted in a loss of steady-state OP91, our second
model MLP (supplementary material Fig. S1G), but had no effect
on either OPG–TASK85 R4 (Fig. 2E, cf. lanes 3 and 4) or Ub-R–
GFP (supplementary material Fig. S1H). Taken together, these
data suggest that the absolute amount of cellular SGTA has a
direct influence on the proteasomal degradation of MLPs. In
contrast to OPG–TASK85, we found that a small fraction of
OP91 is N-glycosylated (Fig. 2D; supplementary material Fig.
S1C,D), indicative of some membrane integration, and this
population showed a modest increase upon coexpression with
SGTA (supplementary material Fig. S1D, see OP91 1-CHO and
2-CHO levels). We conclude that some fraction of newly
synthesised OP91 is most likely a potential substrate for
ERAD, a process in which both BAG6 and SGTA also
participate (Liu et al., 2014; Wang et al., 2011; Xu et al.,
2012), and we therefore employed OPG–TASK85 as our principal
model MLP for further study.
SGTA and BAG6 cooperate to regulate MLP degradation
Our previous work suggested that SGTA influences the
degradation of MLPs by antagonising the actions of the BAG6
complex (Leznicki and High, 2012), and we therefore next asked
whether OPG–TASK85 is a substrate for BAG6-mediated quality
control. An siRNA-mediated knockdown of BAG6 strongly
enhances the steady-state level of OPG–TASK85 (Fig. 3A, cf.
lanes 4 and 5) but, as with SGTA coexpression, there is little
effect upon the R4 variant that lacks a functional hydrophobic
degron (Fig. 3A, cf. lanes 6 and 7). The actions of the BAG6
complex rely on its ability to promote the polyubiquitylation of its
substrates (Hessa et al., 2011; Minami et al., 2010); hence,
replacing the lysine residues present in OPG–TASK85 both
enhances steady-state levels of the resulting OPG–TASK85 DK in
comparison to the parental OPG2TASK85 and negates the effect
of a BAG6 knockdown (Fig. 3A, cf. lanes 4, 5, 8 and 9). We
conclude that OPG2TASK85 is normally degraded through a
pathway that requires the recognition of a contiguous stretch of
hydrophobicity, is facilitated by the BAG6 complex and involves
the ubiquitylation of its lysine side chains. A direct role for the
BAG6 subunit of the BAG6 complex in triaging OPG–TASK85
was underlined by a physical interaction between these two
components that was not observed with OPG–TASK85 R4
(see Fig. 3B,C, cf. lanes 5 to 8). Furthermore, when the BAG6
subunit is exogenously expressed in HeLaM cells, a substantial
proportion of the protein is found in the nucleus (Manchen
and Hubberstey, 2001), resulting in a parallel redistribution of
OPG–TASK85 from the cytosol to the nucleus of cells that
coexpress both components (Fig. 3Di). Nuclear relocalisation of
OPG–TASK85 is not observed with a BAG6 mutant bearing a
Fig. 1. OPG–TASK85 is a mislocalised protein. (A) Schematics of the
OPG–TASK85 and OPG–TASK100 polypeptides comprising the first 26
residues of bovine opsin followed by amino acids 2–60 or 2–75 of TASK-1.
The opsin-derived N-glycosylation sites (Y) and TM1 of TASK-1 (TM 32–54)
are indicated. (B) HeLaM cells were untransfected (lane 1) or transiently
transfected with either OPG–TASK85 (lanes 2 and 3) or OPG–TASK100
(lanes 4 and 5), and total cell lysates were treated with endoglycosidase H
(EndoH) where indicated (+) before analysis by western blotting using an
anti-opsin monoclonal antibody. Singly (closed circle) and doubly (*)
glycosylated forms of OPG–TASK100 are indicated. (C) Cells were prepared
as for B and a portion was removed as a sample of the input (T), and the rest
of the cells were lysed mechanically before separating the membrane (M)
and cytosolic (C) fractions by ultracentrifugation. Equivalent amounts of the
resulting samples were analysed by western blotting using antibodies
against opsin to reveal the TASK-1-derived products and against p23 and
calnexin as markers for the cytosolic and membrane fractions, respectively.
(D) Cells were co-transfected with OPG–TASK85 and RFP (i), OPG–TASK85
(ii) or OPG–TASK100 (iii) as indicated, fixed and analysed for OPG–TASK
(anti-opsin), RFP (direct visualisation) or calnexin (anti-calnexin) by
fluorescence microscopy. Scale bar: 20 mm.
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 4728–4739 doi:10.1242/jcs.155648
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non-functional nuclear localisation signal (Fig. 3Dii) or with the
OPG–TASK85 R4 variant (Fig. 3Diii).
SGTA overexpression delays the proteasomal degradation of
BAG6 substrates
To better define the molecular basis for the increased steady-state
levels of MLPs observed in the presence of exogenous SGTA, we
analysed OPG–TASK85 levels over a 2-hour time course by using
a cycloheximide block to inhibit new protein synthesis (Yewdell
et al., 2011). This approach revealed that in control RFP-
expressing cells, ,50% of OPG–TASK85 was degraded in
30 minutes, whereas it took 120 minutes to achieve a similar
reduction in the presence of exogenous SGTA (Fig. 4A;
supplementary material Fig. S2A). By contrast, the degradation
of OPG–TASK85 R4 appeared to be unaffected by SGTA
overexpression (Fig. 4A; supplementary material Fig. S2A). In
addition to its proposed role in MLP quality control (Leznicki and
High, 2012), SGTA is also implicated in ERAD, and the removal
of unassembled TCRa–YFP from the ER membrane is delayed by
an SGTA knockdown (Xu et al., 2012). Like the MLP OP91, the
opsin degron mutant (OpD) is derived from bovine opsin,
although OpD is a mutant version of full-length opsin that is a
well-defined ERAD substrate (Fleig et al., 2012; Ray-Sinha et al.,
2009). We recently showed that OpD degradation is facilitated by
BAG6 (Payapilly and High, 2014) and therefore asked whether
SGTA also plays any role in OpD quality control. To this end, we
investigated the effect of SGTA overexpression on OpD stability,
and found that it also resulted in a significant delay in OpD
degradation (supplementary material Fig. S2B,C). We conclude
that, like BAG6 (Kawahara et al., 2013), SGTA can influence the
fate of a range of hydrophobic substrates, including both
misfolded and mislocalised membrane proteins.
These data provide evidence that cellular SGTA levels might
directly influence MLP degradation, and we explored the
possibility that this reflects a physical interaction. When labile
or transient protein–protein interactions were stabilised,
by treating cells with the cleavable cross-linking reagent
dithiobis(succinimidylpropionate) (DSP), OPG–TASK85 was co-
immunoprecipitated with SGTA from the resulting cell extracts,
strongly suggesting a direct interaction between these two
components (Fig. 4B,C; lane 6). However, no such interaction
was apparent with OPG–TASK85 R4 (Fig. 4B,C; lane 8),
underlining the importance of substrate hydrophobicity for the
binding of MLPs to SGTA (supplementary material Fig. S1B).
Using a complementary pull-down approach, the ability of in-
vitro-synthesised OPG–TASK85 to bind to recombinant SGTA
was also analysed (Leznicki et al., 2011; Leznicki et al., 2013).
OPG–TASK85 showed robust and specific binding to SGTA
(supplementary material Fig. S2D, cf. lanes 2 and 5 of pulldown),
whereas OPG–TASK85 R4 did not (supplementary material Fig.
S2D, cf. lanes 3 and 6). In short, the substrate specificity of
SGTA shows a striking resemblance to that of BAG6, and the two
components appear to cooperate to control the proteasomal
degradation of MLPs.
Fig. 2. Exogenous SGTA increases steady-state MLP levels. (A) Cells
were left untransfected and untreated (UTF, lanes 1 and 5) or were
transfected with OPG–TASK85 (lanes 2–4) or OPG–TASK85 R4 (lanes 6–8).
Samples were further treated with DMSO (lanes 2 and 6) or 10 nM
bortezomib (BTZ, lanes 4 and 8) for 18 hours or co-transfected with SGTA–
V5 (lanes 3 and 7) before total cell lysates were prepared and analysed by
western blotting. Samples were probed for V5-tagged SGTA and OPG–
TASK85 variants as indicated. Endogenous tubulin provided a loading
control. (B) Cells were co-transfected with a fixed amount of OPG–TASK85
plus a combination of plasmids encoding SGTA–V5 and RFP, such that the
total amount of DNA present was constant. Total cell lysates were analysed
as for A. (C) Schematic of the OP91 polypeptide comprising the first 91
amino acids of bovine opsin, containing two sites for N-linked glycosylation
(Y), the first hydrophobic transmembrane region (TM1) and part of the
second (TM2). (D) HeLa cells were co-transfected with plasmids encoding
OP91 and empty vector (control) or SGTA–V5. Total cell lysates were
analysed at 24 hours after transfection as for A. (E) Cells were transfected
with a control or SGTA-targeting siRNA duplex as indicated and then re-
transfected with OPG–TASK85 (85) or OPG–TASK85 R4 (85 R4). After
24 hours, total cell lysates were analysed by western blotting as before
except endogenous SGTA was detected.
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 4728–4739 doi:10.1242/jcs.155648
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SGTA regulates MLP polyubiquitylation
Our working hypothesis was that SGTA acts by regulating the
polyubiquitylation status of MLPs (Leznicki and High, 2012).
When OPG–TASK85 was coexpressed with a FLAG-tagged
version of ubiquitin and the MLP substrate then recovered
by immunoprecipitation, high-molecular-mass FLAG–ubiquitin-
containing species were readily apparent, consistent with the
efficient polyubiquitylation of OPG–TASK85 (Fig. 5A, lane 1).
The level of these polyubiquitin–OPG–TASK85 conjugates
showed a noticeable qualitative reduction upon SGTA
coexpression (Fig. 5A, cf. lanes 1 and 2). By contrast, SGTA
coexpression had a more modest qualitative effect upon the level
of polyubiquitylated OPG–TASK85 R4 recovered under identical
conditions (Fig. 5A, cf. lanes 3 and 4). The addition of
recombinant SGTA to an established cell-free system for
studying the polyubiquitylation of BAG6 substrates (Leznicki
and High, 2012) also resulted in a marked decrease in the extent
of OPG–TASK85 polyubiquitylation (supplementary material
Fig. S2E, cf. lanes 2–4). Furthermore, when this in vitro system
was employed to enable a ‘pulse-chase’ style analysis of substrate
polyubiquitylation, the addition of exogenous SGTA was found
to promote the deubiquitylation of previously modified OPG–
TASK85 chains (Fig. 5B, cf. lanes 4–6 and 7–9; Fig. 5C).
Taken together, these data support the hypothesis that SGTA
overexpression results in a substantial increase in the steady-state
level of MLPs by promoting their deubiquitylation and, hence,
inhibiting their proteasomal degradation.
SGTA-dependent stabilisation results in substrate
aggregation
When cells expressing either OPG–TASK85 or OP91 were studied
using immunofluorescence microscopy, discrete intracellular
punctae were observed in the presence of exogenous SGTA
(Fig. 6Ai,Bi). These putative cytosolic inclusions contained both
the relevant MLP substrate, be it OPG–TASK85 or OP91, and
SGTA (Fig. 6Ai,Bi, see merge), and were not apparent when the
Fig. 3. OPG–TASK85 is a substrate for BAG6. (A) HeLaM cells
were left untransfected, transfected with an siRNA control (Ctrl) or a
duplex targeting BAG6, as indicated, and then were either not
further manipulated or were re-transfected with OPG–TASK85 (85),
OPG–TASK85 R4 (85 R4) or a lysine-deficient OPG–TASK85 (85
DK). After 24 hours, total cell lysates were analysed by western
blotting. (B,C) Cells were co-transfected with OPG–TASK85 or
OPG–TASK85 R4 and BAG6–V5, as indicated, and 24 hours later,
incubated with DSP (+) or solvent (DMSO) alone (2), quenched
and lysed in buffer containing 0.5% DDM. BAG6–V5 (B) or OPG–
TASK85 (C) were immunoprecipitated (IP) with anti-V5 or anti-opsin,
respectively, and the material recovered was then analysed by
western blotting using 10% of the input for comparison. (D) Cells
were co-transfected with OPG–TASK85 (i,ii) or OPG–TASK85 R4 (iii)
and BAG6–V5 (i,iii) or BAG6–V5 DNLS (ii), as indicated, and were
processed as for Fig. 1D using antibodies recognising OPG–TASK
(anti-opsin tag) and exogenous BAG6 (anti-V5 tag). Scale bar:
20 mm.
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 4728–4739 doi:10.1242/jcs.155648
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MLPs or SGTA were expressed alone (supplementary material
Fig. S3A,B), suggesting that their formation might be substrate
driven. SGTA overexpression also resulted in the appearance
of large inclusions that contained both exogenous SGTA and
the ERAD substrate OpD (supplementary material Fig. S3C,D),
further suggesting that SGTA influences the cellular fate of
both MLPs and ERAD substrates. In the case of the MLPs,
these SGTA-dependent punctae were further characterised
and found to be positive for endogenous BAG6 and HSP70
(Fig. 6Aii,iii,Bii,iii), consistent with a role in quality control,
and they also contained both ubiquitin and proteasomes
(Fig. 6Aiv,v,Biv,v), supporting the suggestion that these structures
are inclusion bodies or aggresomes (Hao et al., 2013). To further
explore the nature of these structures, we made use of ProteoStatH,
a fluorescent red dye that is only detectable when it is bound
to aggregated proteins (Shen et al., 2011). Many of the large
punctate structures observed upon expression of MLPs in the
presence of exogenous SGTA were strongly labelled with
ProteoStatH, further suggesting that they contain protein
aggregates. By contrast, the cytosolic ER delivery factor TRC40
Fig. 4. OPG–TASK85 is protected from degradation by exogenous
SGTA. (A) Cells were co-transfected with plasmids encoding OPG–TASK85
or OPG–TASK85 R4 and SGTA or RFP, as indicated, and 24 hours later,
100 mg/ml cycloheximide was added to the medium and the cells were
harvested directly into sample buffer at the indicated times. The amount of
OPG–TASK85 derivative present at each time-point was determined by
quantitative western blotting, and the resulting value was expressed as a
percentage of the initial level obtained at 0 minutes (see also supplementary
material Fig. S2A). Data show the mean6s.e.m. (n53). (B,C) Cells were co-
transfected with either OPG–TASK85 or OPG–TASK85 R4 and SGTA–V5, as
indicted, and then further processed for co-immunoprecipitation as described
in the legend for Fig. 3B,C.
Fig. 5. SGTA promotes deubiquitylation of MLPs. (A) Cells were co-
transfected with plasmids encoding OPG–TASK85 or OPG–TASK85 R4,
FLAG–ubiquitin and either SGTA–V5 (+) or RFP (2), as shown. After
24 hours, the cells were lysed in RIPA buffer, specific products recovered by
immunoprecipitation (IP) with anti-opsin, and the resulting samples analysed
for FLAG–ubiquitin by western blotting (lanes 1–4). A 10% fraction of each
input was analysed in parallel (lanes 5–8). Bands corresponding to
polyubiquitylated products (vertical line) and antibody chains (*) are indicated.
(B) OPG–TASK85 was synthesised using rabbit reticulocyte lysate and, after
termination of further translation initiation using ATCA, 2 mM of either
recombinant HisTrx–SGTA or HisTrx control was added and samples were
incubated for the times indicated before NEMwas added to prevent any further
modifications. Samples were then treated with DTT and pre-cleared in
immunoprecipitation buffer containing 1% Triton X-100 using pansorbin. After
centrifugation to clarify, immunoprecipitation was performed overnight with
Protein-A–Sepharose and the indicated antibodies or an IgG control. The resin
was washed and samples were analysed by SDS-PAGE and
phosphorimaging. (C) High-molecular-mass species recovered following
immunoprecipitation with the anti-opsin antibody were quantified for each time-
point shown in B, and the resulting values were expressed as a percentage of
the signal recovered at time 0. Data show the mean6s.e.m. (n53).
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was not detected in the MLP-positive cytosolic inclusions
(supplementary material Fig. S4A), and there was little overlap
between SGTA-positive punctae and the lysosomal marker LAMP1
(supplementary material Fig. S4B), consistent with the inability of
lysosomal protease inhibitors to prevent MLP degradation
(supplementary material Fig. S1C). The OP91-positive inclusions
observed upon SGTA overexpression were also clearly distinct from
both the ER and Golgi, consistent with a cytosolic localisation
(supplementary material Fig. S4C).
Aberrant and misfolded precursor proteins are often
aggregation prone (Ast and Schuldiner, 2011; Ast et al., 2013),
and we investigated the status of SGTA-stabilised MLPs using
selective detergent solubilisation. Under control conditions,
all detectable OP91 was recovered in a Triton-X-100-soluble
fraction (Fig. 6C, cf. lanes 2 and 3), yet we found that a
substantial proportion of the non-glycosylated form of OP91 was
found in the insoluble pellet fraction upon SGTA coexpression
(Fig. 6C, cf. lanes 5 and 6, see OP91 0-CHO). Such behaviour is
strongly indicative of cytosolic aggregation (Chakrabarti et al.,
2011) and, together with our imaging data, suggests that the
cytosolic inclusions that we observe in the presence of exogenous
SGTA represent aggresomes or aggresome-like structures
(Rodriguez-Gonzalez et al., 2008).
Recent structural studies have revealed a central role for the N-
terminal region of SGTA in facilitating its binding to the BAG6
complex, through its UBL-domain-containing subunits (Chartron
et al., 2012; Simon et al., 2013; Xu et al., 2012). Because our
data show that both BAG6 and SGTA bind to MLPs and
colocalise to cytoplasmic MLP-containing inclusions upon SGTA
overexpression, we asked whether the BAG6 complex contributes
to the SGTA-dependent stabilisation of MLPs. Several studies
have defined the molecular basis for the binding of specific UBLs
to SGTA family members (Chartron et al., 2012; Simon et al.,
2013; Xu et al., 2012), and we chose to make a V34A variant of
SGTA that preserves its dimerisation interface whilst reducing
its affinity for cognate UBLs by approximately two orders of
magnitude (see Chartron et al., 2012; Simon et al., 2013).
Strikingly, although the V5-tagged SGTA(V34A) variant was
expressed at a level comparable to that of the parental SGTA–V5,
its ability to enhance steady-state MLP levels was greatly reduced
(Fig. 6D). These data strongly suggest that the stabilisation of
MLPs observed upon SGTA overexpression is dependent upon
efficient binding of exogenous SGTA to the endogenous BAG6
complex. On the basis of these data, we conclude that MLP
substrates, exemplified here by OPG–TASK85 and OP91, enter a
cytosolic quality control pathway that is mediated by the BAG6
complex and SGTA working in tandem (Hessa et al., 2011;
Kawahara et al., 2013; Leznicki et al., 2013).
DISCUSSION
When Sec61-mediated protein translocation at the ER is inhibited,
for example using a small molecule inhibitor or following a stress
response, the resulting non-translocated membrane and secretory
proteins mislocalise to the cytosol and are rapidly degraded unless
proteasomal degradation is blocked (Besemer et al., 2005; Kang
et al., 2006). Furthermore, there is good evidence that regions of
exposed hydrophobicity, including unembedded transmembrane
domains act as a potent signal to elicit the degradation of such
MLPs (Huang et al., 2011). Recent studies suggest that MLP
degradation is selective, and they have directly implicated two key
factors, SGTA (Leznicki and High, 2012) and the BAG6 complex
(Hessa et al., 2011), as mediators of this process (Fig. 7). Here, we
have developed model MLPs and exploited them to study the role
of SGTA during MLP quality control.
SGTA binds to MLPs
Our studies show that SGTA binds directly to MLPs, both in vitro
and in vivo, and underline the importance of an uninterrupted
hydrophobic degron for this interaction to occur. Crucially, the
ability of an aberrant protein to bind to SGTA directly impacts on
the role that SGTA plays in its quality control, strongly
suggesting that its actions are direct. Most strikingly, although
OPG–TASK85 R4 is clearly a substrate for proteasomal
degradation, and hence is stabilised by the proteasome inhibitor
bortezomib, it does not associate with SGTA and its stability is
unaffected by either increasing or decreasing the level of SGTA.
By contrast, OPG–TASK85 shows a robust interaction with SGTA
and its steady-state expression level and stability are directly
correlated with the amount of SGTA present in a cell. Reductions
in SGTA by siRNA treatment reduce OPG–TASK85 levels,
whereas exogenous expression of SGTA has the opposite effect.
These findings extend the substrate base for SGTA from the in
vitro binding of tail-anchored membrane proteins and the glucose
transporter (Leznicki et al., 2010; Leznicki et al., 2011; Liou and
Wang, 2005) to include the in vivo binding of a model MLP.
SGTA substrate specificity overlaps with that of the BAG6
complex
There is extensive evidence for a physical interaction between
SGTA and the BAG6 complex (see Chartron et al., 2012;
Leznicki et al., 2013; Simon et al., 2013; Xu et al., 2012 and
references therein), as well as evidence that exposed
hydrophobicity is an important feature of protein substrates that
are dealt with by the BAG6 complex (Kawahara et al., 2013).
Strikingly, the in vivo interactions of MLPs with the BAG6 protein
mirror those of SGTA, hence BAG6 binds to OPG–TASK85 but not
to OPG–TASK85 R4. This substrate specificity is very clearly
demonstrated by the ability of exogenous BAG6 to relocalise
OPG–TASK85 to the nucleus, a finding that mirrors the BAG6-
dependent nuclear relocalisation of the ERAD substrate OpD
(Payapilly and High, 2014). Taken together, these data are
consistent with a model where hydrophobic substrates located in
the cytosol can be passed between SGTA and the BAG6 complex
(Fig. 7), a process that might be facilitated by a fast exchange
between these two cellular quality control components (Chartron
et al., 2012). One important, but as yet unanswered, question is
how SGTA and BAG6 are able to distinguish different classes of
hydrophobic substrate and deal with them appropriately. Hence,
whereas tail-anchored membrane proteins are passed to TRC40 for
subsequent ER delivery, MLPs and ERAD substrates are normally
efficiently degraded at the proteasome (Fig. 7). The molecular
basis for this apparent substrate selectivity is currently unclear.
SGTA regulates MLP degradation
We now show that the cellular basis for the previously reported
increase in steady-state MLPs following SGTA overexpression
(Leznicki and High, 2012) is a consequence of the selective
inhibition of their proteasomal degradation. Furthermore, we
find that SGTA overexpression also delays the proteasomal
degradation of the ERAD substrate OpD, confirming that, like
BAG6 (Kawahara et al., 2013), SGTA contributes to the quality
control of a range of hydrophobic substrates. Although we find
that SGTA overexpression stabilises both a model MLP and an
ERAD substrate, it remains to be established whether the
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physiological role of SGTA during these two processes is
comparable (Fig. 7). Interestingly, several recent reports
correlate increases in SGTA expression with the proliferation of
several forms of cancer, although the molecular basis for this
observation remains to be defined (Lu et al., 2014; Philp et al.,
2013; Xue et al., 2013).
On the basis of the data presented in this study, we propose that
the molecular mechanism underlying the increase in steady-state
Fig. 6. SGTA promotes the aggregation of mislocalised proteins. (Ai–v) HeLa Flp-In T-REx cells that stably express OPG–TASK85 under the control of a
tetracycline-inducible promoter were transiently transfected with SGTA–V5 and induced to express OPG–TASK85. (Bi–v) HeLaM cells were co-transfected with
plasmids encoding OP91 and SGTA–V5. For A and B, at 24 hours post-transfection, samples were processed for microscopy to examine the subcellular
localisation of the relevant MLP (anti-opsin), exogenous SGTA (anti-V5) and various endogenous components, including BAG6 (ii), Hsp70 (iii), ubiquitin (iv) and
the 20S proteasomal subunit (v), and visualised by immunofluorescence. (Avi,Bvi) HeLaM cells were co-transfected with plasmids encoding OPG–TASK85 or
OP91 and SGTA–V5, and stained using an anti-opsin antibody to detect MLP substrates and ProteoStatH to visualise protein aggregates. Enlarged sections
(insets) highlight cytosolic inclusions that resemble aggresomes (see text). Scale bars: 20 mm. (C) HeLaM cells were co-transfected with plasmids encoding
OP91 and RFP (lanes 1–3) or SGTA–V5 (lanes 4–6) and, 24 hours later, they were solubilised in buffer containing 1% Triton X-100. The resulting lysate was
centrifuged to separate soluble and insoluble material and then equivalent amounts of supernatant (S) and pellet (P), together with 10% of the total lysate
(T), were analysed by western blotting as described for Fig. 2. (D) HeLaM cells were co-transfected with plasmids encoding OP91 and GFP (lane 1), SGTA–V5
(lane 2) or SGTA–V5(V34A) (lane 3) and, after 24 hours, were further processed for western blotting as before.
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MLP levels observed upon SGTA overexpression occurs through
an effect on MLP polyubiquitylation status, with increased levels
of SGTA favouring the deubiquitylated form of MLPs both in vitro
and in vivo. Taken in a wider context, these data support the
operation of a cytosolic quality control cycle for hydrophobic
substrates (Fig. 7). This cycle would be driven by the opposing
actions of SGTA and the BAG6 complex, a proposal that is
supported by our finding that for exogenous SGTA to
stabilise MLPs it must be able to interact with the endogenous
BAG6 complex (Fig. 6D). We favour a model where an
artificial increase in the level of SGTA promotes substrate
deubiquitylation, and our in vitro data support this proposal
(Fig. 5B; Leznicki and High, 2012). However, the binding of
exogenous SGTA to MLP substrates and/or the BAG6 complex
might also act to directly inhibit their ubiquitylation in vivo (Fig. 7)
through a pathway that almost certainly involves the E3 ligase
RNF126 (Rodrigo-Brenni et al., 2014). Our current hypothesis is
that the pronounced stabilisation of MLPs observed upon
SGTA overexpression provides a non-physiological example of a
‘rescue’ pathway that would normally favour certain hydrophobic
substrates such as tail-anchored membrane proteins. In this
scenario, the possibility to deubiquitylate precursor proteins that
undergo premature ubiquitylation could prolong their window of
opportunity for post-translational membrane integration (Fig. 7;
cf. Leznicki and High, 2012). Interestingly, a comparable cycle
of ubiquitylation and deubiquitylation has been suggested to
provide quality control for hydrophobic GPI-anchored protein
precursors that fail to engage the ER translocation machinery in
Saccharomyces cerevisiae (Ast et al., 2014). Deubiquitylases can
also enhance the substrate selectivity of proteasomal degradation
(Liu et al., 2014; Zhang et al., 2013) and, in this context, a BAG6/
SGTA-dependent cycle of ubiquitylation and deubiquitylation
might fine-tune the fate of distinct hydrophobic substrates that
become exposed to the cytosol (Fig. 7).
SGTA overexpression promotes protein aggregation
Having established that SGTA overexpression inhibits the
proteasomal degradation of aberrant membrane proteins, we
explored the intracellular fate of these aberrant polypeptides.
Immunofluorescence microscopy revealed that both our model
MLPs and ERAD substrate are localised to discrete intracellular
punctae when coexpressed with SGTA but not in its absence. In
the case of the ERAD substrate OpD, these structures are
comparable to those observed with TCRa–YFP upon SGTA
depletion (Xu et al., 2012). In the case of the MLPs, these
cytoplasmic punctae co-stain for both exogenous SGTA and
endogenous BAG6; in addition to Hsp70 chaperones, ubiquitin
and 20S proteasomal subunits, suggesting that they represent
aggregated MLPs or aggresomes. This proposal is further
supported by our observations that SGTA-stabilised forms of
OPG–TASK85 and OP91 are selectively stained with ProteoStatH,
whilst a substantial proportion of SGTA-stabilised OP91 is also
recovered in a detergent-insoluble form, both strongly indicative
of protein aggregation (Chakrabarti et al., 2011; Shen et al.,
2011). On the basis of these data, we tentatively suggest that the
MLP-containing punctae observed upon SGTA overexpression
represent structures that are related to cytoplasmic juxtanuclear
quality control compartments (Ben-Gedalya and Cohen, 2012).
These are dynamic sites for cellular quality control where
substrates might be either deubiquitylated and subjected to
chaperone-mediated refolding, or ubiquitylated and directed to
the proteasome for degradation (Ben-Gedalya and Cohen, 2012).
Our data suggest that an unperturbed BAG6/SGTA quality
control cycle promotes the biogenesis of selected hydrophobic
precursors at the ER, whilst also facilitating the removal of
aberrant and misfolded membrane proteins. Together, these
actions will decrease the opportunities for such hydrophobic
proteins to form cytosolic aggregates and reduce their potential
impact upon cellular proteostasis (Buchberger et al., 2010;
Chakrabarti and Hegde, 2009; Hartl et al., 2011; Park et al.,
2013; Fig. 7).
MATERIALS AND METHODS
Materials
All cell culture and standard reagents were purchased from Sigma. The
region of bovine opsin used as an N-glycosylation reporter and epitope
tag was as described previously (Johnson et al., 2012). Anti-TRC40
serum was a gift from Bernhard Dobberstein (ZMBH, Heidelberg,
Germany). Commercially available antibodies against the following
Fig. 7. A potential BAG6/SGTA cycle for cytosolic
quality control. Hydrophobic polypeptides that fail to
engage SRP, including tail-anchored (TA) proteins and
short fragments of integral membrane proteins, become
substrates for both SGTA and the BAG6 complex (step 1).
Tail-anchored proteins are most likely passed from SGTA
to the BAG6 complex before specific transfer to the ER
delivery factor TRC40 (step 2; see Chartron et al., 2012;
Leznicki et al., 2010; Mariappan et al., 2010). By contrast,
the binding of MLPs to the BAG6 complex promotes their
ubiquitylation (Rodrigo-Brenni et al., 2014) and
proteasomal degradation (step 3), a process that is
antagonised by SGTA (Leznicki and High, 2012). We
postulate that SGTA normally acts to provide a rescue
pathway for prematurely ubiquitylated substrates (step 4),
thereby prolonging their opportunity for successful ER
delivery and/or native folding. SGTA overexpression
causes the inhibition and/or reversal of BAG6-mediated
MLP ubiquitylation (step 5), resulting in their accumulation
and aggregation.
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targets were purchased from the indicated suppliers: BAG6, BAP31, GFP,
tubulin and V5 (Abcam), FLAG M2 and calnexin (Sigma), HSP70
(Stressgen), ubiquitin FK2, p23, 20S proteasome (Enzo Life Sciences) and
LAMP1 (DHSB, University of Iowa). The antibody against GRASP65 was
a gift from Martin Lowe (University of Manchester, UK). ProteoStatH
reagent for the detection of protein aggregates was from Enzo. Bortezomib
was from Selleck Chemicals, leupeptin and pepstatin A were from
BIOMOL. RFP in pcDNA3.1+ was a gift from Viki Allan (Manchester,
UK). siRNA duplexes for knockdowns were from Qiagen, and they
targeted sequences that were identified previously (Winnefeld et al., 2006):
SGTA target sequence, 59-TTTGAAGCTGCCGTGCATT-39; BAG6
target sequence, 59-CAGCTCCGGTCTGATATACAA-39.
Plasmids
Fragments of TASK-1 without cysteine residues (C14V), TASK85 and
TASK100 were subcloned, with the first 26 amino acids of bovine opsin at
the N-terminus, into pcDNA3.1+ (Life Technologies), generating OPG–
TASK constructs. OPG–TASK85 was also subcloned into pcDNA5/FRT/
TO (Life Technologies). SGTA and BAG6 were in pcDNA5/FRT/V5-
His-TOPO in frame to add the V5 tag. OP91, OP91CHO and eGFP were
in the same vector, but with stop codons prior to the tag. Ub-R–GFP was
obtained through Addgene (Dantuma et al., 2000). The FLAG–ubiquitin
construct was a gift from Sylvie Urbe´ (University of Liverpool, UK).
BAG6 DNLS, SGTA V34A, OPG–TASK85 R4 and the lysine-deficient
mutant were generated by using the QuikChange site-directed
mutagenesis kit (Stratagene).
Cell culture
HeLa and HeLaM cells were maintained in DMEM containing 10% fetal
bovine serum and 2 mM L-glutamine at 37 C˚ under 5% CO2. DNA
transfections were performed using Lipofectamine 2000 (Life
Technologies) for 24 hours in accordance with the manufacturer’s
instructions. For siRNA experiments, 20 nM siRNA duplexes were
transfected using INTERFERin (Polyplus) as specified by the
manufacturer. The cells were then transiently transfected with the
appropriate DNA constructs after 48 hours and harvested for analysis
after 72 hours. The inducible stable HeLa cell line expressing OpD was
as described previously (Payapilly and High, 2014), whereas the OPG–
TASK85 was generated for this study using HeLa Flp-In T-REx cells,
which were a gift from Stephen Taylor (University of Manchester, UK;
Tighe et al., 2008). For drug treatments, 10 nM bortezomib, 100 mM
leupeptin and 1 mg/ml pepstatin were added at 18 hours prior to analysis.
Subcellular fractionation
Transfected HeLaM cells were lysed mechanically using a ball-bearing
cell cracker with 10-mm clearance in buffer containing 20 mM HEPES-
KOH pH 7.4, 100 mM KCl and 5 mM MgCl2. Unbroken cells and large
debris were removed by centrifugation at 2000 g for 10 minutes. The
membrane and cytosolic fractions were separated by ultra-centrifugation
at 100,000 g for 10 minutes at 4 C˚.
Western blotting
Samples were prepared for western blotting and specific proteins were
detected as described previously (Leznicki and High, 2012).
Quantification was performed using Image Studio (Li-Cor Biosciences)
employing data from at least three independent experiments. When used,
endoglycosidase H (New England Biolabs) was added at 20 units/ml
directly to material in SDS sample buffer and samples were incubated at
37 C˚ for at least 3 hours.
Co-immunoprecipitation
Co-transfected HeLaM cells were solubilised in 10 mM Tris-HCl pH 7.4,
150 mM NaCl and 1 mM EDTA supplemented with protease inhibitor
cocktail, 1 mM PMSF and 0.5% n-dodecyl b-D-maltopyranoside (DDM)
for 1 hour at 4 C˚. Where indicated, cells were treated with the cleavable
cross-linking reagent dithiobis(succinimidylpropionate) (DSP, Pierce)
at 1 mM for 15 minutes at room temperature and then quenched with
10 mM glycine prior to the addition of the DDM lysis buffer. To recover
FLAG-tagged ubiquitin conjugates, cells were lysed in RIPA buffer
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5%
sodium deoxycholate and 0.1% SDS) containing protease inhibitors, 1 mM
PMSF and 20 mM N-ethylmaleimide (NEM) and then sonicated. Insoluble
material was removed by centrifugation at 16,000 g for 10 minutes at 4 C˚,
10% of the supernatant was retained as the input sample, and the remainder
used for the immunoprecipitation of specific proteins using an appropriate
antibody and Protein-A–Sepharose (Genscript).
Cycloheximide chase and in vitro ubiquitylation assay
The stability of OPG–TASK derivatives was studied by treating
transfected HeLaM cells with 100 mg/ml cycloheximide (Sigma) and
lysing them directly in SDS-PAGE sample buffer at the indicated time-
points prior to analysis by western blotting. For OpD, a stable inducible
cell line was transfected with plasmids encoding GFP or V5-tagged
SGTA, and samples were processed as described previously (Payapilly
and High, 2014). In vitro ubiquitylation of OPG–TASK derivatives in the
presence of HisTrx or HisTrx–SGTA was performed as described
previously (Leznicki and High, 2012). AIDA software was used to
quantify the resulting polyubiquitylated material.
In vitro SGTA-binding assay
OPG–TASK85 or OPG–TASK85 R4 were translated in reticulocyte lysate
reactions containing 35S-methionine/cysteine and supplemented with
2 mM HisTrx–SGTA or HisTrx (Leznicki and High, 2012). To terminate
the translation, samples were incubated in the presence of 1 mM
puromycin for 10 minutes at 30 C˚. A 10% sample of the input was
retained for analysis, and the remaining reaction was diluted to give a
final volume of 150 ml with buffer containing 50 mM HEPES-KOH
pH 7.5, 300 mM NaCl, 50 mM imidazole, 10% glycerol and 10 ml (bead
volume) Ni-NTA agarose (Qiagen). After incubation for 2 hours at 4 C˚
with shaking, the agarose was washed three times with 1 ml of buffer as
above, before elution in 30 ml of buffer containing 500 mM imidazole.
The resulting samples were analysed by SDS-PAGE, and radiolabelled
products were detected by phosphorimaging.
Selective detergent solubility analysis
Transfected HeLaM cells were solubilised in 10 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA containing 1% (v/v) Triton X-100, protease
inhibitor cocktail and 1 mM PMSF for 30 minutes at 4 C˚. A 10% input
sample was taken and the soluble and insoluble materials were isolated
by centrifugation at 16,000 g for 30 minutes at 4 C˚.
Immunofluorescence microscopy
Cells grown on glass coverslips were transiently transfected using jetPEI
(Polyplus) for HeLaM cells (OP91 expression) and Fugene HD (Promega)
for the OPG–TASK85 and OpD stable cell lines, which were also induced
for 16–24 hours with 1 mg/ml tetracycline prior to analysis. For
ProteoStatH staining, HeLaM cells were co-transfected with the SGTA–
V5 construct and plasmids encoding OPG–TASK85 or OP91 using Fugene
HD. Fixation was performed using 4% paraformaldehyde, and cells were
permeabilised with 0.1% Triton X-100, except for LAMP1 staining where
methanol fixation (220 C˚, 5 minutes) was performed. Alexa-Fluor-488-
conjugated and Alexa-Fluor-594-conjugated secondary antibodies were
from Jackson ImmunoResearch, the ProteoStatH reagent for detection of
protein aggregates was from Enzo Life Sciences and DNA was stained
using 49,6-diamidino-2-phenylindole (DAPI). Coverslips were mounted
using Prolong Gold (Life Technologies) and fluorescence was visualised
using a wide-field Olympus BX-60 microscope with a 606/1.40 NA
PlanApo objective and a CoolSnap ES camera (Roper Scientific), with
images captured using MetaVue software.
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